Mythbuster Monday: Compounded Medications Are Not As Effective As FDA-Approved Options
On Mythbuster Monday, we tackle a variety of equestrian myths to either bust or confirm. Today’s discussion: Are compounded medications as effective as FDA-approved options?
It’s Mythbuster Monday, where Horse Nation dives into different equestrian myths and provides research-based evidence to either bust or confirm those myths.
Today’s Mythbuster Monday was inspired by an online debate in a horse group, so we decided to dig deeper, look at the science behind it, and separate myth from fact. So, here it is — are compounded medications as effective as the FDA approved options? Why are they not all FDA approved? What is the difference between the two? Read on to find out!
Myth: Compounded medications are not as effective as the FDA-approved option
Myth or Fact: Both
When discussing medications in the equine world, two terms that often are mentioned are FDA-approved medications and compounded medications. While both are used in veterinary medicine, they are created and regulated in very different ways. Understanding these differences is important for horse owners, trainers, and veterinarians as they work together to make treatment decisions for performance horses, pleasure horses, and everything in between.
FDA-approved medications are drugs that have gone through a formal review process by the U.S. Food and Drug Administration to evaluate their safety, effectiveness, quality, and consistency. These medications are manufactured under strict standards and are labeled with specific dosing instructions, ingredients, and approved uses. In equine medicine, FDA-approved drugs are commonly used for conditions ranging from pain management and ulcers to infections and sedation.
Compounded medications, on the other hand, are customized formulations prepared by a pharmacist or veterinarian to meet an individual horse’s specific needs. A compounded medication may involve altering the form of a drug, combining ingredients, or creating a dosage strength that is not commercially available. Compounding can play an important role in veterinary medicine when a horse cannot easily receive a standard medication or when a commercially manufactured product is unavailable. However, compounded medications do not go through the same FDA approval process as commercially manufactured drugs, which creates important distinctions in oversight, consistency, and intended use.
But, are compounded medications as effective as their FDA-approved counterparts?
Canva/CC
The review article, Compounding of Veterinary Drugs for Equine Practitioners, examines the role of compounded medications in equine medicine and provides a balanced discussion that directly relates to the common belief that compounded drugs are not as effective as FDA-approved medications. Rather than arguing that compounded medications are inherently ineffective, the authors emphasize that compounded drugs can vary significantly in quality, potency, stability, and absorption because they are not subjected to the same rigorous approval and manufacturing standards as FDA-approved products. The article explains that FDA-approved medications undergo extensive testing to demonstrate safety, efficacy, consistency, and stability, whereas compounded medications may lack published data confirming that they consistently deliver the intended therapeutic effect. The authors stress that this variability is one of the main concerns surrounding compounded equine medications and is the reason veterinarians should approach them cautiously.
However, the article also makes it clear that compounded medications still have an important place in equine practice when used appropriately. The authors recognize that many horses require customized formulations because commercially available FDA-approved drugs may not exist in the needed dose, concentration, route, or formulation. Instead of dismissing compounded drugs altogether, the review recommends that their use should be veterinary-driven, evidence-based, and limited to situations where safety, efficacy, and stability have been demonstrated or where therapeutic response can be carefully monitored. This creates a more nuanced perspective on the myth. The article suggests the issue is not simply that compounded medications “do not work,” but rather that their effectiveness and reliability may be less predictable if proper compounding standards and supporting evidence are lacking. In other words, the concern centers more on consistency and quality assurance than on the idea that all compounded medications are automatically inferior to FDA-approved options.
Canva/CC
Veterinary Compounding: Regulation, Challenges, and Resources provides a broad examination of veterinary compounding practices and offers important insight into the debate surrounding whether compounded medications are as effective as FDA-approved drugs. The article explains that compounded medications are widely used in veterinary medicine because there are often limited approved drug options available for different animal species, including horses. Compounding allows veterinarians and pharmacists to alter dosage forms, concentrations, or flavors to better suit individual animal needs. However, the authors emphasize that compounded medications come with important scientific and regulatory concerns that can directly affect therapeutic reliability. Specifically, the article discusses issues such as inconsistent formulation quality, lack of validated compounding formulas, reduced bioavailability, and variability in potency between compounded batches. These concerns are important because they can lead to unpredictable drug absorption and therapeutic response compared to FDA-approved medications, which undergo strict testing for safety, effectiveness, manufacturing consistency, and stability.
At the same time, the article does not conclude that compounded medications are automatically ineffective or inappropriate. Instead, it presents compounding as a necessary and valuable tool in veterinary medicine when commercially available approved products cannot meet the needs of a specific patient. The review highlights that compounded drugs may improve medication compliance, allow treatment of conditions where approved therapies do not exist, and provide alternative dosage forms for difficult-to-medicate animals. However, the authors repeatedly stress that the effectiveness of compounded medications depends heavily on the quality of the compounding process and adherence to appropriate standards. One of the major themes of the article is that the lack of consistent regulatory oversight in veterinary compounding contributes to uncertainty regarding product quality and clinical reliability. As a result, the article supports a more nuanced interpretation of the myth: the concern is not necessarily that compounded medications “do not work,” but that their performance may be less predictable because they are not routinely subjected to the same rigorous testing and quality control standards required of FDA-approved drugs.
Canva/CC
Pharmacokinetic and Pharmacodynamic Effects of 2 Registered Omeprazole Preparations and Varying Dose Rates in Horses examined how two different FDA-registered omeprazole formulations performed in horses and provides important insight into the discussion surrounding compounded versus FDA-approved medications. Researchers compared an established enteric-coated omeprazole paste with a newer granule formulation and found significant differences in pharmacokinetic measurements such as plasma drug concentrations, absorption rates, and overall bioavailability between the two products. Even though both products were registered and designed to deliver the same active ingredient, the way the medications were formulated altered how the drug behaved in the horse’s body. The study demonstrated that formulation characteristics, including delivery method and coating, can greatly influence how effectively a medication is absorbed and how long therapeutic effects last. This is highly relevant to the myth surrounding compounded medications because it reinforces the idea that even small formulation differences can affect drug performance in horses.
However, despite measurable differences in drug absorption and plasma concentrations, both omeprazole products still improved gastric pH and reduced ulcer severity in horses. One of the study’s most important conclusions was that higher plasma drug concentrations did not always directly predict better therapeutic outcomes. This finding creates a more nuanced understanding of medication effectiveness in horses. Rather than supporting the idea that non-standard formulations are automatically ineffective, the article suggests that formulation quality and pharmacodynamics are complex and cannot be judged solely by whether a product is compounded or commercially approved. At the same time, the research highlights why consistency and formulation testing matter so much in equine medicine. Because absorption and therapeutic response can vary significantly between products, veterinarians must carefully evaluate whether a compounded or alternative formulation has evidence supporting its stability, bioavailability, and clinical performance before assuming it will behave the same as an FDA-approved medication.
Canva/CC
Across veterinary pharmacology literature, equine medicine reviews, and regulatory research, a consistent picture emerges: compounded medications can play an important and necessary role in horse care, but their effectiveness and reliability depend heavily on formulation quality, stability, and evidence supporting their use. While FDA-approved medications undergo rigorous testing for safety, efficacy, consistency, and bioavailability, compounded medications do not routinely face the same level of standardized evaluation. The research does not support the blanket claim that compounded medications are automatically ineffective in horses. Instead, the literature consistently shows that concerns center around variability in potency, absorption, formulation consistency, and quality control, all of which can influence therapeutic response. Importantly, studies demonstrate that even commercially registered formulations of the same drug can differ significantly in bioavailability and pharmacokinetic behavior, reinforcing how greatly formulation itself matters in equine medicine. Rather than proving compounded medications “do not work,” the current body of evidence suggests that their clinical reliability may be less predictable when compared to FDA-approved products unless they are produced using validated formulations and appropriate compounding standards.
Do you have an equine myth you’d like us to tackle? If so, send it our way! Email your suggestions to [email protected]. Put Mythbuster Monday in your subject line.
